Glioblastoma is the most common and aggressive type of primary brain tumor, with an average survival rate of 15 months, ...

Chloride ion flows that enter the cells play an important role in the duplication of glioblastoma cells, a highly aggressive ...

Research provides evidence that a drug used to slow the progression of the disease ALS shows promise in suppressing the self-renewing cancerous stem cells that challenge the present standards of care ...

A promising ALS drug may help combat glioblastoma by targeting the cancerous stem cells that fuel tumor growth.

A recent study has revealed that chloride flow through channels on the surface of tumor cell lines plays a crucial role in ...

Violets' cyclotides could revolutionize glioblastoma treatment by boosting chemotherapy efficacy, now advancing to mouse ...

Brussels, Belgium, 8 October 2024. A groundbreaking study1 led by Dr Monika E. Hegi, MD, PhD and European Organisation for ...

The Glioblastoma Research Organization (GBMRO), a nonprofit organization raising awareness and funds for cutting-edge research to find a cure for glioblastoma, is hosting its inaugural Glioblastoma ...

Diakonos’ dendritic cell vaccine represents a unique approach for engaging an immune response against a patient’s cancer.

In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall ...

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report). The associated ...